 |
|
|
|
|
|
|
|
 |
Results for 'The Emerging Drug Targets Outlook' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
100 % |
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
|
August 2004 |
£415 |
97 % |
Emerging Diabetes Drugs
Competitor Analysis
|
November 2008 |
£410 |
49 % |
Proteins
Strategies for Optimizing Drug Discovery
|
January 2004 |
£1000 |
46.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£4345 |
41.5 % |
Model Animal Systems
Emerging Applications and Commercial Opportunities in Drug Discovery and Development
|
June 2004 |
£1946 |
40.5 % |
Drug Delivery Technologies
Current Market Dynamics, Future Market Opportunities and Lifecycle Strategies
|
September 2008 |
£1450 |
36.5 % |
Analytical Tool: Apoptosis
Promise or deception?
|
May 2007 |
£2600 |
36 % |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
May 2007 |
£2600 |
34.5 % |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1260 |
32.5 % |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
May 2007 |
£2600 |
32 % |
The Exploding RNAi Market & Future Direction
Translating the Genome into a Large Market by 2009
|
February 2001 |
£955 |
32 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2895 |
32 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2895 |
30 % |
Mergers & Acquisitions in Pharmaceuticals
When and how
|
February 2000 |
£165 |
28 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£2055 |
28 % |
Injectable Drug Delivery: Market Impact and Industry Trends
|
October 2006 |
£1175 |
27.65 % |
Insulin
Competitor Analysis
|
October 2008 |
£275 |
27.5 % |
RNAi 2004
Strategic Opportunities
|
January 2004 |
£1995 |
27.5 % |
Proteomics
|
June 2003 |
£1995 |
27 % |
Analytical Tool: Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£4155 |
26.5 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£1615 |
26.5 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2895 |
26.5 % |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
August 2008 |
£740 |
26.25 % |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1599 |
26.25 % |
Nigeria Pharmaceuticals and Healthcare Report Q3 2007
|
September 2007 |
£360 |
26 % |
GLP-1 Receptor Agonists
Competitor Analysis
|
November 2008 |
£140 |
26 % |
Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain
|
January 2008 |
£1499 |
25.9 % |
U.S. Next Generation Bio-Tools for Accelerating Bio-Pharmaceutical Drug Discovery R&D
Technologies, Opportunities and Market
|
March 2001 |
£1400 |
25.55 % |
Analytical Tool – Hematological Cancers
|
May 2007 |
£4995 |
25.5 % |
Early Toxicology
Markets and Approaches
|
June 2007 |
£2345 |
25.5 % |
Analytical Tool - Analysis of Colorectal Cancer R&D
The Complete Guide
|
September 2005 |
£2600 |
25.5 % |
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies
|
June 2006 |
£2600 |
25.5 % |
Dynamic Antibody Industry
|
August 2005 |
£3045 |
25.5 % |
Analytical Tool - Leukemia Therapeutics & Competitive Insights
|
May 2007 |
£2600 |
24.5 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
24.5 % |
Analytical Tool: Lymphoma Therapeutics & Competitive Insights
|
May 2007 |
£2600 |
24.5 % |
Life Science Tools and Technologies for Bio-Pharma R&D
Instruments, Tech Platforms, Informatics and Market
|
March 2003 |
£1005 |
24.5 % |
Analytical Tool - Targeted Therapeutics: Melanoma
|
July 2007 |
£2600 |
24 % |
Analytical Tool: Prostate Cancer
A Therapeutic & Competitive Insight
|
May 2007 |
£2600 |
24 % |
Analytical Tool: Breast Cancer R&D Comprehensive Guide
|
May 2007 |
£2600 |
24 % |
Stakeholder Opinions: Biologics in Infectious Diseases
Well Defined Target Populations Are Key to Commercial Success
|
March 2008 |
£2005 |
23.8 % |
Stakeholder Opinions: Nosocomial Infections
The need for new gram-negative drugs
|
March 2007 |
£2005 |
23.5 % |
Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
|
May 2007 |
£2600 |
23.5 % |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1635 |
23 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1880 |
22.5 % |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1260 |
22.5 % |
Drug Discovery Tools for High-Content Analysis
|
July 2007 |
£1340 |
21.35 % |
Biosimilars: Benchmarking the key players
With increasing regulatory clarity and high revenue potential, interest in biosimilars increases
|
December 2006 |
£4000 |
21.35 % |
Monoclonal Antibodies Report
|
June 2008 |
£3800 |
21.35 % |
Drug Discovery Technology
A Combination Of Opportunities
|
June 2001 |
£1615 |
21 % |
Innovations in The Management of Diabetes
Next generation treatments and market dynamics
|
June 2008 |
£1995 |
21 % |
Emerging U.S. Biopharmaceutical Companies
New Drug R&D and Investment /Partnership Opportunities
|
April 2001 |
£735 |
20.65 % |
Monoclonal Antibodies Report Part I
|
June 2007 |
£3800 |
20.65 % |
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Equipment, Technologies and Companies, 2006-2011
|
January 2007 |
£1105 |
20.3 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
20.3 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
20 % |
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy
Stakeholder Opinions
|
December 2007 |
£2005 |
19.95 % |
Global Functional Genomics Industry
|
November 2002 |
£1840 |
19.5 % |
Molecular Imaging Comes of Age
Applications and Impacts in Discovery, Clinical Trials, and Medical Practice
|
October 2004 |
£1950 |
19.25 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
18.9 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
18.5 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£2055 |
17.85 % |
Biotech 2010
|
June 2006 |
£3255 |
17.5 % |
Late Stage Deals
Strategy, Structure and Payment Terms
|
August 2004 |
£950 |
17 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
17 % |
Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
|
August 2001 |
£1105 |
16.8 % |
Puerto Rico Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
16 % |
Stakeholder Insight: Asthma
Combination Therapy Appropriate for Everyone?
|
January 2005 |
£8000 |
15.75 % |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1635 |
15.5 % |
The Future Of Array Technologies
Impact on drug discovery and market growth in DNA, protein and tissue arrays
|
January 2005 |
£1495 |
15.4 % |
Optimizing Targeted Treatment in Cancer
Negotiating the Challenges to Success
|
September 2005 |
£1000 |
15.05 % |
The Future of Systems Biology
Emerging technologies and their impact on drug discovery, development and diagnostics
|
January 2005 |
£1495 |
14.7 % |
Emerging Drug Discovery Technologies
Building competitive advantage through lab-on-a-chip, nanotechnology and RNAi
|
January 2005 |
£1495 |
14.7 % |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
14 % |
Anti-Obesity Treatments 2007-2012 - A blockbuster target market
|
July 2007 |
£1799 |
14 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3355 |
14 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
14 % |
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity
R&D Strategies
|
August 2007 |
£7600 |
13.65 % |
Emerging Generic Drug Companies Worldwide 2007
|
February 2007 |
£595 |
13 % |
A New Paradigm for Clinical Development
The Clinical Trial in 2015
|
November 2005 |
£1945 |
12.95 % |
The Future of Metabolomics
Building competitive advantage in drug discovery, clinical development and diagnostics
|
August 2006 |
£1495 |
12.95 % |
Biotech Drug Delivery Systems
Key Company Intelligence & Market Outlook to 2012
|
February 2007 |
£1299 |
12.95 % |
Innovations in Bioinformatics
Emerging Tools for Drug Discovery and Development
|
January 2008 |
£1995 |
12.6 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
12.6 % |
Biomarkers & Related Tests for Molecular Diagnostics & Pharma/ Biotech R&D
Companies, Products & Worldwide Market, 2004-2009
|
July 2005 |
£1270 |
12.6 % |
Translational Medicine In Biopharmaceutical R&d
Enabling R&d Optimization And Early Detection Of Potential Failures
|
October 2007 |
£1495 |
12.25 % |
Outsourcing Clinical Trials
A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index
|
May 2007 |
£2010 |
12.25 % |
Genomics World Markets
|
May 2008 |
£2280 |
12.25 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
12.25 % |
Pipeline Insight: Chronic and Acute Heart Failure
Diversity and Disappointment
|
December 2005 |
£6495 |
12.25 % |
Antibiotics and Drug Resistance 2008
Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms
|
January 2008 |
£1499 |
12.25 % |
Australia Pharmaceuticals & Healthcare
|
July 2006 |
£395 |
12 % |
Urinary Tract Agents Report 2005
|
April 2005 |
£1499 |
12 % |
Hematological Cancer Therapeutics
Pipelines and Competition
|
September 2005 |
£2140 |
11.9 % |
Pipeline Insight: Nosocomial Vaccines
Minefield or Goldmine?
|
April 2008 |
£6000 |
11.55 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
11.55 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3045 |
11.55 % |
Cytogenetics
technologies,markets and companies
|
September 2008 |
£1340 |
11.5 % |
Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets
Reshaping Tomorrow's Diabetes Market
|
October 2005 |
£1340 |
11.2 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£2345 |
11.2 % |
Bioinformatics Report
The forecasts and future of the market 2006-2011
|
October 2006 |
£1499 |
10.85 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
10.85 % |
Diabetes Drug Pipeline
Competitor Analysis
|
November 2008 |
£410 |
10.5 % |
Microarray Markets
|
September 2008 |
£1340 |
10.5 % |
Kinase Inhibitors
|
January 2006 |
£3255 |
10.15 % |
Biotech in Autoimmune and Inflammatory Disease 2006
2nd Edition
|
May 2006 |
£2010 |
10.15 % |
Biosimilars Series
Strategic Issues - Potential Remains Uncertain
|
October 2007 |
£2005 |
10.15 % |
RNA Interference Markets
|
September 2008 |
£1340 |
9.8 % |
Medical Nanotechnology Markets
|
September 2008 |
£2280 |
9.45 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£5835 |
9.45 % |
ADME/TOX Technologies
|
January 2008 |
£1960 |
9.1 % |
DNA Sequencing and PCR Markets
|
July 2008 |
£2280 |
8.75 % |
Stakeholder Opinions: Osteoarthritis
Preconceptions Damage Awareness and Treatments
|
March 2006 |
£2195 |
8.4 % |
Commercial and Pipeline Insight: Systemic antifungals
|
November 2007 |
£7600 |
8.4 % |
Gene Expression Reagents Markets
|
April 2007 |
£1340 |
8.05 % |
Molecular Diagnostics Markets
|
September 2008 |
£2280 |
8.05 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
7.7 % |
Veterinary Drug Residues & MRLs
|
January 2006 |
£795 |
7.35 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1015 |
7.35 % |
Commercial Insight: Cardiovascular market overview
Raft of patent expires threaten blockbusters
|
October 2007 |
£7600 |
7 % |
Protein Therapeutics Market; The
The Science and Business of a Growing Sector
|
June 2006 |
£2615 |
7 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£285 |
7 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£285 |
6.65 % |
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
|
July 2007 |
£7600 |
6.65 % |
Animal Biotechnology
Technologies, Markets and Companies
|
September 2008 |
£900 |
6.3 % |
Commercial Insight: Antidyslipidemics
Branded statins beware, generics are amongst you
|
July 2006 |
£8440 |
5.95 % |
High Throughput Screening
|
January 2008 |
£2060 |
5.6 % |
Metabolomics
|
January 2008 |
£1850 |
5.6 % |
Manufacturing in the Global Pharmaceuticals Industry
Key drivers, company strategies and regulations (3rd Edition)
|
September 2008 |
£1160 |
4.55 % |
Global Vaccines Market 2008-2023, The
|
August 2008 |
£1499 |
4.55 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
September 2008 |
£3020 |
3.5 % |
|
|
|
|
